Inevitability of disease recurrence after liver transplantation for NAFLD cirrhosis

Villeret, François; Dharancy, Sébastien; Erard, Domitille; Abergel, Armand; Barbier, Louise; Boillot, Olivier; Boudjéma, Karim; Coilly, Audrey; Conti, Filoména; Corpechot, Christophe; Duvoux, Christophe; Faitot, François; Faure, Stéphanie; Francoz, Claire; Giostra, Emiliano; Gugenheim, Jean; Hardwigsen, Jean; Hilleret, Marie‐Noëlle; Hiriart, Jean‐Baptiste; Houssel‐Debry, Pauline; Kamar, Nassim; Lassailly, Guillaume; Latournerie, Marianne; Pageaux, Georges‐Philippe; Samuel, Didier; Vanlemmens, Claire; Saliba, Faouzi; Dumortier, Jérôme

doi:10.1016/j.jhepr.2022.100668

Cited by 14 publications

(10 citation statements)

References 35 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…However, ALD patients with few elements of metabolic syndrome were classified as ALD in the present study, even if they would be classified now as MetALD alcohol predominant in the new nomenclature. Alcohol and metabolic syndrome are frequently implicated in liver graft injury since they initially led to liver failure and LT. Recurrent NAFLD has been reported from 24.0% to 88.2% and steatohepatitis in 30%–40% of LT patients for NAFLD 18,31 . In a meta‐analysis of 2166 patients, pooled prevalence of de novo fatty liver graft disease was globally of 26% and of 37% in patients transplanted for ALD 32 .…”

Section: Discussionmentioning

confidence: 99%

“…28 In 2020, to liver failure and LT. Recurrent NAFLD has been reported from 24.0% to 88.2% and steatohepatitis in 30%-40% of LT patients for NAFLD. 18,31 In a meta-analysis of 2166 patients, pooled prevalence of de novo fatty liver graft disease was globally of 26% and of 37% in patients transplanted for ALD. 32 In two recent studies with longer follow-up, the prevalence of de novo fatty liver graft disease was higher of 56.4 and 53.0%.…”

Section: What Are the Determinants Of Fatty Liver Graft Disease?mentioning

confidence: 99%

See 1 more Smart Citation

Dual alcohol and metabolic‐related liver disease: Results from a population of liver transplant patients

Erard,

Villeret,

Chouik

et al. 2023

Liver International

Self Cite

View full text Add to dashboard Cite

Background & AimsIf alcohol‐related liver disease (ALD) and nonalcoholic fatty liver disease (NAFLD) are now the two main indications for liver transplantation (LT), it has been recognized that both conditions can coexist in varying degrees and the concept of dual‐aetiology fatty liver disease (DAFLD) has been proposed. This retrospective study aimed to evaluate, in a cohort of patients transplanted for ALD and NAFLD, the prevalence of DAFLD before LT and the impact on liver graft outcome.MethodsFrom 1990 to 2010, all patients who underwent LT for the so‐called ALD or NAFLD in our centre were included. Before LT, DAFLD was defined as patients with a history of excessive alcohol consumption and obesity associated with either diabetes or hypertension. Before LT, patients were separated into three groups: DAFLD, ALD, and NAFLD. Fatty liver graft disease was classified according to the FLIP algorithm.ResultsOut of 907, adult LT recipients were identified: 33 DAFLD patients, 333 ALD patients, and 24 NAFLD patients. After LT, ALD patients experienced significantly more alcohol relapse than DAFLD patients, who had twice more post‐LT metabolic syndrome. Out of 926, post‐LT biopsies, DAFLD patients had significantly more fatty liver graft disease due to metabolic syndrome features than ALD patients.ConclusionOur results support that DAFLD recently emerged as an indication of LT. In the future, this particular population needs to be identified as a specific entity since post‐LT outcome on the graft is different from ALD and more similar to NAFLD patients.

show abstract

Section: Discussionmentioning

confidence: 99%

Section: What Are the Determinants Of Fatty Liver Graft Disease?mentioning

confidence: 99%

Dual alcohol and metabolic‐related liver disease: Results from a population of liver transplant patients

Erard,

Villeret,

Chouik

et al. 2023

Liver International

Self Cite

View full text Add to dashboard Cite

show abstract

“…Studies have indicated that up to 30%-40% of patients may experience graft steatosis, which refers to the accumulation of fat in the transplanted liver. 45,46 EMERGING THERAPIES FOR MASLD…”

Section: Liver Transplantationmentioning

confidence: 99%

“…One of the primary concerns is the recurrence of MASLD in the transplanted liver. Studies have indicated that up to 30%–40% of patients may experience graft steatosis, which refers to the accumulation of fat in the transplanted liver 45,46 …”

Section: Current Therapies For Masldmentioning

confidence: 99%

Advancements in metabolic‐associated steatotic liver disease research: Diagnostics, small molecule developments, and future directions

Eeda,

Patil,

Joshi

et al. 2024

Hepatology Research

View full text Add to dashboard Cite

Metabolic (dysfunction) associated steatotic liver disease (MASLD) formerly known as non‐alcoholic fatty liver disease (NAFLD) is a growing global health concern with no approved pharmacological treatments. At the same time, there are no standard methods to definitively screen for the presence of MASLD because of its progressive nature and symptomatic commonality with other disorders. Recent advances in molecular understanding of MASLD pathophysiology have intensified research on development of new drug molecules, repurposing of existing drugs approved for other indications, and an educated use of dietary supplements for its treatment and prophylaxis. This review focused on depicting the latest advancements in MASLD research related to small molecule development for prophylaxis or treatment and diagnosis, with emphasis on mechanistic basis at the molecular level.This article is protected by copyright. All rights reserved.

show abstract

“…In detail, after 5 years from LT, recurrent graft steatosis and NASH may be present in approximately 80% and 60% of patients transplanted for NASH cirrhosis, respectively. Some authors argue that the recurrence of the disease is essentially inevitable [89]. In a recent meta-analysis, it was reported that the development of recurrent graft steatosis is five times more likely than de novo MASL [OR: 5.38 (2.69-10.76)].…”

Section: De Novo and Recurrent Maslmentioning

confidence: 99%

Metabolic Disorders in Liver Transplant Recipients: The State of the Art

Gabrielli,

Golfieri,

Nascimbeni

et al. 2024

JCM

View full text Add to dashboard Cite

Liver transplantation represents a chief therapeutic approach for acute liver failure, end-stage liver disease and hepatocellular carcinoma. Despite witnessing advancements in short- and medium-term survival over recent decades, attributed to refinements in surgical techniques and immunosuppressive protocols, long-term mortality remains impervious to modification. Notably, cardiovascular disease emerges as a predominant cause of mortality among liver transplant recipients. This trend is accentuated by the increasing prominence of non-alcoholic steatohepatitis-related cirrhosis as an indication for liver transplantation. Moreover, the administration of immunosuppressive agents is intricately linked to the degradation of the metabolic profile in liver transplant recipients, thereby contributing to the initiation or exacerbation of cardiovascular risk factors, such as hypertension, diabetes, and dyslipidaemia. In addition, the post-liver transplantation period is marked by a decline in lifestyle quality and a failure to acknowledge the psychological distress experienced by patients throughout the transplant process. These factors can precipitate a deterioration in the patient’s metabolic profile, exacerbated by suboptimal therapeutic compliance. This narrative review aims to comprehensively address the principal metabolic disorders intricately associated with liver transplantation.

show abstract

Inevitability of disease recurrence after liver transplantation for NAFLD cirrhosis

Cited by 14 publications

References 35 publications

Dual alcohol and metabolic‐related liver disease: Results from a population of liver transplant patients

Dual alcohol and metabolic‐related liver disease: Results from a population of liver transplant patients

Advancements in metabolic‐associated steatotic liver disease research: Diagnostics, small molecule developments, and future directions

Metabolic Disorders in Liver Transplant Recipients: The State of the Art

Contact Info

Product

Resources

About